+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 39 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating molnupiravir, a study medicine designed to stop the COVID-19 virus from multiplying, to see if it can prevent severe illness from COVID-19 more effectively than a placebo in people who are at high risk. The focus is on non-hospitalized adults with COVID-19 who have certain health conditions or factors that increase their chance of severe illness, which can require hospitalization or lead to death. Participants will be randomly assigned to receive either 800 mg of molnupiravir orally every 12 hours for 5 days a total of 10 doses or a matching placebo on the same schedule. Some participants may also receive remdesivir as standard care if clinically appropriate. This is a phase 3, double-blind, placebo-controlled study comparing molnupiravir versus placebo. During the study, participants will be monitored for up to 29 days for outcomes such as hospitalization, death, and COVID-19-related medically attended visits. Researchers will assess adverse events and discontinuation due to side effects over approximately 5 months. Other measures include tracking symptom relief, changes in virus levels, and need for medical interventions. The total participation duration covers treatment and follow-up monitoring to evaluate safety and effectiveness.

Age: 18Years +All GendersPhase 3
227 locations
C

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a new approach to prevent cardiovascular events in people at increased risk due to age and conditions like diabetes, prediabetes, or metabolic syndrome but who do not have symptoms of cardiovascular disease. The study compares a personalized care strategy based on the Cleerly Coronary Artery Disease CAD Staging System with the usual risk factor-based care. This approach aims to better identify and treat individuals with underlying atherosclerosis to reduce cardiovascular events. Participants are randomly assigned to one of two groups. The risk factor-based care group is managed by their usual healthcare providers, with oversight from a centralized cardiology team that monitors treatments and lab results without seeing coronary imaging results. The Cleerly stage-based care group receives personalized management from a remote cardiologist-led team using the Cleerly CAD Staging System, which includes coronary artery imaging, algorithm-driven medication adjustments, and education. Care is intensified if plaque worsens at 24 months. During the study, participants undergo assessments including coronary computed tomography angiography CCTA and lab tests. Researchers monitor cardiovascular events over an average of 3.5 years to compare the two care strategies. Medication use, lab values, and clinical outcomes related to cardiovascular and kidney health are tracked. The study includes electronic communication tools to support personalized care and aims to improve prevention through more precise disease staging and management.

Age: 55Years +All GendersPhase Not Applicable
125 locations
R

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and treatment experience of participants prescribed BRIUMVI4 ublituximab-xiiy for relapsing multiple sclerosis RMS in a real-world setting. The study aims to gather insights over time on how this treatment works outside of controlled clinical trials. Participants will receive BRIUMVI4 ublituximab-xiiy through intravenous infusion as part of their routine care for RMS. This observational study follows these participants longitudinally to monitor their health and treatment experience without assigning any new interventions. During the study, participants will be monitored for relapses, adverse events, and infusion-related reactions up to 96 weeks. Researchers will collect data from medical records and routine visits to assess annualized relapse rates and safety outcomes, supporting a comprehensive understanding of treatment effects in everyday clinical practice. The study duration extends until 2032, allowing for long-term follow-up.

Age: 18Years +All Genders
113 locations
S

Actively Recruiting

Researchers are evaluating the effects of experimental drugs pozelimab and cemdisiran in adults aged 50 to 85 with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD, a condition affecting central vision. The study aims to compare the progression rate of GA in patients treated with cemdisiran alone, pozelimab combined with cemdisiran, and a placebo, while also examining side effects, drug levels in the blood, and immune responses to the drugs. Participants are randomly assigned to one of three groups pozelimab plus cemdisiran, cemdisiran alone, or placebo. All treatments are given by subcutaneous injection. The study is double-masked and placebo-controlled, lasting up to 104 weeks for key outcome measures, with extended safety monitoring up to 296 weeks. The trial includes multiple visits for evaluations and treatments over this period. During the study, participants undergo detailed eye imaging using Fundus Autofluorescence to measure GA lesion growth, assessments of visual acuity, and contrast sensitivity tests at weeks 52 and 104. Blood samples are collected to measure drug concentrations and immune responses, including antibodies against the drugs. Safety is monitored throughout the study and during extended follow-up. Participants adherence to clinic visits and vaccinations is required for participation.

Age: 50Years - 85YearsAll GendersPhase 3
231 locations
S

Actively Recruiting

Researchers are evaluating how well amivantamab combined with lazertinib or with chemotherapy works in treating participants with epidermal growth factor receptor mutated EGFRm non-small cell lung cancer NSCLC, a common type of lung cancer. This Phase 2b study focuses on patients whose NSCLC is locally advanced or metastatic and who have specific EGFR mutations. The study aims to assess antitumor activity and treatment effects over time. Participants are assigned to one of two treatment groups. One group receives subcutaneous amivantamab combined with oral lazertinib in 28-day cycles, and the other group receives subcutaneous amivantamab combined with intravenous platinum-based chemotherapy carboplatin and pemetrexed in 21-day cycles. Treatment continues until disease progression, withdrawal, death, or investigator decision. The study is open-label and non-randomized, consisting of two parallel cohorts. During the study, participants will undergo regular assessments to monitor tumor response and safety. Key measures include progression-free survival tracked for up to 4 years and 6 months, along with evaluations of adverse events, overall survival, response rates, and duration of response. Researchers will also monitor dose changes and specific side effects such as venous thromboembolic events and dermatologic reactions. Participation may last several years depending on individual treatment and disease course.

Age: 18Years +All GendersPhase 2
205 locations
R

Actively Recruiting

Researchers are studying Raludotatug Deruxtecan R-DXd, an antibody-drug conjugate that targets CDH6 protein, in people with platinum-resistant, high-grade ovarian, primary peritoneal, or fallopian tube cancer. This trial includes a Phase 2 dose-optimization part to find the best dose based on safety and effectiveness, followed by a Phase 3 part comparing R-DXd to chemotherapy chosen by the investigator. Participants will receive R-DXd through an intravenous infusion every three weeks at varying doses during Phase 2. In Phase 3, participants will be randomly assigned to receive either R-DXd at the recommended dose or one of the chemotherapy options paclitaxel, pegylated liposomal doxorubicin PLD, or topotecan, also given intravenously every three weeks. During the study, participants will undergo scans and biopsies to evaluate tumor response and drug effects. Researchers will monitor safety, side effects, and various measures such as progression-free survival and overall survival for up to 40 months. Participants will have regular visits for treatment, assessments, and laboratory tests to track their health and response to the study treatments.

Age: 18Years +All GendersPhase 2Phase 3
167 locations
G

Actively Recruiting

Researchers are evaluating the safety of telisotuzumab vedotin in adults with previously treated non-squamous non-small cell lung cancer NSCLC that overexpresses the c-Met protein. This phase 2, open-label study aims to assess treatment-emergent adverse events, changes in disease activity, and how the drug behaves in the body. Approximately 150 participants will be enrolled worldwide and randomly assigned to one of three telisotuzumab vedotin dose groups. Participants will receive intravenous infusions of telisotuzumab vedotin at different doses as a monotherapy, administered over a three-year study period. The study compares three dosing regimens given by IV infusion, with participants assigned to one of three groups in a 111 ratio. Each participant will be treated and followed for up to three years to monitor safety and response. During the study, participants will attend regular visits at hospitals or clinics for medical assessments, blood tests, and monitoring of side effects. Questionnaires will be completed to report symptoms and quality of life. Researchers will track adverse events, including lung disease, neuropathy, and eye disorders, as well as treatment response and survival outcomes. The study includes ongoing safety monitoring and evaluation of drug levels in the blood throughout the treatment period.

Age: 18Years +All GendersPhase 2
83 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of neoadjuvant carboplatin combined with mirvetuximab soravtansine in adult women with advanced-stage serous epithelial ovarian, fallopian tube, or primary peritoneal cancer that expresses folate receptor alpha FR. This phase 2, single-arm study focuses on patients with stage III or IV disease confirmed by specific diagnostic criteria. Mirvetuximab soravtansine is an investigational antibody drug conjugate designed to selectively target and kill cancer cells expressing FR. Participants receive intravenous infusions of mirvetuximab soravtansine together with carboplatin on day 1 of each 21-day cycle, for up to 6 to 9 cycles. Bevacizumab may also be given at the investigators discretion. The treatment is provided in a hospital or clinic setting. The total study duration, including treatment and follow-up, is approximately three years. During the study, participants attend regular visits for medical assessments, blood tests, and imaging scans to monitor their condition and treatment response. Researchers will evaluate the objective response to treatment by independent central review and investigator assessments, as well as safety through adverse event monitoring. Additional measures include progression-free survival, disease control, symptom changes, and surgery outcomes. The study aims to understand how well the treatment works and its safety profile over the course of the trial.

Age: 18Years +FEMALEPhase 2
73 locations
S

Actively Recruiting

Researchers are evaluating the safety and tolerability of IMGN151, an investigational drug, when given alone or combined with other anti-cancer therapies in adults with gynecologic cancers, including ovarian, fallopian tube, and primary peritoneal cancers. This Phase 2 study involves around 377 participants worldwide and aims to assess how well these treatments are tolerated and their effects on disease activity. Participants are assigned randomly to one of six treatment groups. Each group receives intravenous infusions of IMGN151 either alone or combined with carboplatin, olaparib taken orally twice daily, or bevacizumab on Day 1 of a 21-day cycle. The study duration is about three years, with treatment cycles repeated accordingly. Different arms explore the drugs combination with standard therapies or as monotherapy across various patient populations. During the study, participants will attend regular hospital or clinic visits for medical assessments, blood tests, and imaging scans. Researchers will monitor for dose-limiting toxicities and adverse events throughout the study, along with measuring objective response, duration of response, and progression-free survival. This close monitoring helps ensure participant safety and gather important data over the course of treatment and follow-up.

Age: 18Years +FEMALEPhase 2
21 locations
C

Actively Recruiting

Researchers are investigating new treatment options for people with proficient mismatch repair pMMR endometrial cancer that is advanced or has returned after surgery. This cancer begins in the lining of the uterus and has either spread locally or to other parts of the body, making surgery not an option. The study aims to compare combining sacituzumab tirumotecan sac-TMT with pembrolizumab against pembrolizumab alone to see if it helps patients live longer without the cancer worsening. Participants first receive an Induction Phase treatment of six cycles every three weeks involving pembrolizumab plus either carboplatin or cisplatin combined with paclitaxel or docetaxel. If the cancer does not progress, they move to a Maintenance Treatment Phase where they are randomly assigned to receive pembrolizumab with sac-TMT or pembrolizumab alone. If the cancer progresses, participants may enter a Subsequent Treatment Phase with random assignment to pembrolizumab plus sac-TMT or sac-TMT alone. Treatments are given by intravenous infusion following specific dosing schedules over several months. Throughout the study, participants undergo regular assessments including scans to evaluate cancer progression, monitoring for side effects, and quality of life questionnaires. Researchers will measure progression-free survival and overall survival up to approximately 44 and 54 months respectively. The study also tracks adverse events and changes in physical and role functioning. The total participation can last up to several years with careful monitoring to assess treatment outcomes and safety.

Age: 18Years +FEMALEPhase 3
268 locations

1-10 of 39

1